anurajms/meta_analysis huggingface dataset:
outcomes:
Fibrin glue for pilonidal sinus disease
1. Allergic Reaction 2. Seroma 3. Wound Healing
outcomes:
Intensive case management for severe mental illness
1. Withdrawn From Research Study 2. Relapse 3. Death 4. Duration Of Hospital Stay 5. Mental State Finding 6. Hospitalization 7. Assessment Using Social Functioning Scale 8. Global Assessment
outcomes:
Protease‐modulating matrix treatments for healing venous leg ulcers
1. Venous leg ulcer 2. Wound Healing 3. Adverse Event
outcomes:
Non‐steroidal anti‐inflammatory drugs for sciatica
1. Disability 2. Pain Scale 3. Functional ability 4. Adverse Event 5. Clinical Improvement 6. Pain Intensity
outcomes:
Lung volume reduction surgery for diffuse emphysema
1. Quality of Life 2. Death
outcomes:
Fast‐track cardiac care for adult cardiac surgical patients
1. Stroke 2. Death 3. Length Of Stay 4. Duration Of Hospital Stay 5. Extubation Of Trachea 6. Intensive Care 7. Endotracheal Reintubation 8. Time-to-Event 9. Postoperative Myocardial Infarction
outcomes:
Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults
1. Oxygenation Index 2. Death 3. Renal Impairment 4. Fraction Of Inspired Oxygen 5. Mechanical ventilation 6. Partial Arterial Pressure Of Oxygen
outcomes:
Manual therapy and exercise for rotator cuff disease
1. Pain 2. Shoulder Joint Painful On Movement 3. Treatment Success 4. Quality of Life 5. Global Assessment 6. Adverse Event 7. Functional ability
outcomes:
Back schools for acute and subacute non‐specific low‐back pain
1. Disability 2. Pain 3. Sick Leave 4. Adverse Event
outcomes:
Risperidone (depot) for schizophrenia
1. Relapse 2. Mental State Finding 3. Glucose 4. Adverse Event 5. Nervous system disorder 6. Patient-Reported Outcome 7. Movement Disorder 8. Withdrawn From Research Study 9. Serious Adverse Event 10. Prolactin 11. Pyramidal Sign 12. Weight Gain 13. Global Assessment
outcomes:
Surgical versus conservative interventions for treating anterior cruciate ligament injuries
1. Serious Adverse Event 2. Treatment Failure 3. Quality of Life
outcomes:
Care delivery and self management strategies for adults with epilepsy
1. Quality of Life 2. Seizure 3. Demonstrates Knowledge Of Medication Management 4. Drug toxicity
outcomes:
Motor control exercise for chronic non‐specific low‐back pain
1. Disability 2. Visual Analog Pain Scale 3. Pain 4. Pain Scale 5. Adverse Event 6. Pain Intensity
outcomes:
Multi‐disciplinary rehabilitation for acquired brain injury in adults of working age
1. Disability 2. Impairment 3. Quality of Life 4. Hospitalization 5. Psychosocial functioning
outcomes:
Crisis intervention for people with severe mental illnesses
1. Manchester Short Assessment 2. Duration Of Hospital Stay 3. Mental State Finding 4. Hospitalization 5. Global Assessment 6. Patient Satisfaction
outcomes:
Rehabilitation for distal radial fractures in adults
1. Serious Adverse Event 2. Quality of Life 3. Functional ability
outcomes:
Early versus delayed dressing removal after primary closure of clean and clean‐contaminated surgical wounds
1. Surgical Site Infection 2. Serious Adverse Event 3. Costs and Cost Analysis 4. Hospitalization 5. Wound Dehiscence
outcomes:
Social skills programmes for schizophrenia
1. Relapse 2. Quality of Life 3. Mental State Finding 4. Hospitalization 5. Social functioning 6. Global Assessment 7. Functional ability
outcomes:
Cognitive‐behavioural treatment for subacute and chronic neck pain
1. Disability 2. Kinesiophobia 3. Pain 4. Pain Scale
outcomes:
Use of plastic adhesive drapes during surgery for preventing surgical site infection
1. Surgical Site Infection
outcomes:
Supportive therapy for schizophrenia
1. Withdrawn From Research Study 2. Relapse 3. Quality of Life 4. Hospitalization 5. Global Assessment 6. Functional ability 7. Patient Satisfaction
outcomes:
Hydrogel dressings for treating pressure ulcers
1. Pain 2. Pressure ulcer 3. Wound Healing 4. Adverse Event 5. Wound Infection
outcomes:
Protocolized versus non‐protocolized weaning for reducing the duration of mechanical ventilation in critically ill adult patients
1. Weaning From Mechanically Assisted Ventilation 2. Death 3. Intensive Care 4. Endotracheal Reintubation 5. Mechanical ventilation 6. Time-to-Event
outcomes:
Minimally invasive discectomy versus microdiscectomy/open discectomy for symptomatic lumbar disc herniation
1. Sensory Deficit 2. Visual Analog Pain Scale 3. Oswestry Disability Index 4. Surgical Site Infection 5. Reflex Finding 6. Low back pain 7. Hospitalization 8. Roland-Morris Disability Questionnaire 9. Return to Work 10. Health-Related Quality of Life 11. Disability 12. Leg Pain 13. Pain 14. Incontinence 15. Neurological Deficit 16. Deficits In Attention Motor Control And Perception 17. Activities Of Daily Living Assessment 18. Sciatica
outcomes:
Platelet‐rich therapies for musculoskeletal soft tissue injuries
1. Disability 2. Visual Analog Pain Scale 3. Pain 4. Adverse Event 5. Functional ability
outcomes:
Bronchial thermoplasty for moderate or severe persistent asthma in adults
1. Serious Adverse Event 2. Quality of Life 3. Death 4. Hospitalization 5. Asthma Control 6. Adverse Event 7. Asthma exacerbation 8. Rescue Medication 9. Health-Related Quality of Life
outcomes:
Trifluoperazine versus placebo for schizophrenia
1. Relapse 2. Serious Adverse Event 3. Behavior 4. Hospitalization 5. Clinical Global Impression
outcomes:
Enhanced care by generalists for functional somatic symptoms and disorders in primary care
1. Quality Of Life Scale 2. Patient Status
outcomes:
User‐held personalised information for routine care of people with severe mental illness
1. Violence 2. Hospital admission 3. Death 4. Suicide
outcomes:
Traction for low‐back pain with or without sciatica
1. Disability 2. Patient Global Impression of Improvement 3. Functional ability 4. Adverse Event 5. Return to Work 6. Pain Intensity
outcomes:
Dressings for superficial and partial thickness burns
1. Wound observation 2. Wound Healing 3. Time-to-Event
outcomes:
Inhaled corticosteroids for subacute and chronic cough in adults
1. Clinical Cure 2. Adverse Event 3. Cough 4. Clinical Improvement 5. Patient-Reported Outcome
outcomes:
Nurse versus physician‐led care for the management of asthma
1. Quality of Life 2. Hospitalization 3. Asthma exacerbation
outcomes:
Percutaneous nephrolithotomy versus retrograde intrarenal surgery for treatment of renal stones in adults
1. Complication
outcomes:
Totally tubeless, tubeless, and tubed percutaneous nephrolithotomy for treating kidney stones
1. Postoperative Pain 2. Serious Adverse Event
outcomes:
Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease
1. Kidney disease 2. Falls 3. Healthcare costs 4. End Stage Kidney Disease 5. Blood Pressure 6. Hospital admission 7. Quality of Life 8. Death 9. Fatigue 10. Cardiovascular disease 11. Adverse Event 12. Dementia
outcomes:
Interventions for improving health literacy in people with chronic kidney disease
1. Health literacy 2. Chronic Kidney Disease
outcomes:
Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis
1. Venous Stenosis 2. Vascular access site thrombosis 3. Clinical Resolution
outcomes:
Interventions for minimal change disease in adults with nephrotic syndrome
1. All Cause Mortality 2. Renal remission 3. Cardiovascular Event 4. Decreased Renal Function 5. Acute Renal Failure 6. Adverse Event 7. Thrombosis
outcomes:
Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy
1. Continuous Renal Replacement Therapy 2. Death 3. Complication
outcomes:
Aldosterone antagonists for people with chronic kidney disease requiring dialysis
1. Gynaecomastia 2. All Cause Mortality 3. Cardiovascular observations 4. Hyperkalaemia 5. Cardiovascular Mortality 6. Cerebrovascular Disease
outcomes:
Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy
1. Thrombocytopenia 2. Increased Renal Function 3. All Cause Mortality 4. Costs and Cost Analysis 5. Treatment Success 6. Withdrawal Due To Adverse Events 7. Major Bleed
outcomes:
Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults
1. Ureteric Stone 2. Quality of Life 3. Kidney Stone 4. Adverse Event
outcomes:
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease
1. Renal Failure 2. Cardiovascular Event 3. Acute Renal Failure 4. Serum Creatinine 5. Hyperkalaemia 6. Death 7. Estimated glomerular filtration rate 8. Proteinuria
outcomes:
Calcium channel blockers for people with chronic kidney disease requiring dialysis
1. Systolic Blood Pressure 2. Diastolic Blood Pressure 3. Blood Pressure 4. Cardiovascular Mortality 5. Intradialytic hypotension 6. Adverse Event 7. Iatrogenic Hypotension
outcomes:
Oral protein‐based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis
1. Body Mass Index 2. Costs and Cost Analysis 3. Mass Of Body Structure 4. Body weight 5. C-reactive Protein level 6. Serum Potassium 7. Mid-upper arm circumference 8. Muscle Finding 9. Interleukin-6 10. Serum Albumin 11. Serum Phosphate 12. Increased Intolerance 13. Prealbumin 14. Gastrointestinal Irritation 15. Quality of Life 16. Death 17. Skin thickness 18. Nutritional status
outcomes:
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
1. Thrombocytopenia 2. BK virus infection 3. Rash 4. Glomerular Filtration Rate 5. Tremor 6. Leukopenia 7. Anemia 8. Measurement Of Serum Triglyceride Level 9. Acne 10. Diabetes Mellitus 11. Lymphoma 12. Acute Rejection Of Renal Transplant 13. Treatment Changed 14. Post-transplant Lymphoproliferative Disorder 15. All Cause Mortality 16. Graft loss 17. Hypercholesterolemia 18. Wound Complication 19. Hypertriglyceridemia 20. Cytomegalovirus Infection 21. Cholesterol Analyses 22. Cancer
outcomes:
Interventions for preventing bone disease in kidney transplant recipients
1. Graft loss 2. All Cause Mortality 3. Bone Pain 4. Cardiovascular Mortality 5. Fracture 6. Spinal deformity 7. Hypocalcemia 8. Acute Rejection Of Renal Transplant
outcomes:
Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis
1. All Cause Mortality 2. Stroke 3. Discomfort 4. Low Blood Pressure 5. Withdrawal Due To Adverse Events 6. Acute Coronary Syndrome
outcomes:
Catheter type, placement and insertion techniques for preventing catheter‐related infections in chronic peritoneal dialysis patients
1. Peritoneal Dialysis Catheter Exit Site Infection 2. All Cause Mortality 3. Removal Of Peritoneal Dialysis Catheter 4. Treatment Failure 5. Peritoneal Dialysis Catheter Tunnel Infection 6. Replacement Of Peritoneal Dialysis Catheter 7. Peritonitis
outcomes:
Alpha‐blockers as medical expulsive therapy for ureteral stones
1. Serious Adverse Event 2. Pain 3. Ureteric Stone 4. Surgery 5. Hospitalization 6. Time-to-Event 7. Therapeutic Response 8. Expulsion 9. Diclofenac
outcomes:
Medical and dietary interventions for preventing recurrent urinary stones in children
1. Dietary Regime 2. Drug Therapy 3. Kidney Stone 4. Adverse Event
outcomes:
Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease
1. End Stage Kidney Disease 2. Uric acid measurement 3. Cardiovascular Event 4. Disease Progression 5. Serum Creatinine 6. Death 7. Chronic Kidney Disease 8. Estimated glomerular filtration rate 9. Renal Dialysis
outcomes:
Terlipressin versus other vasoactive drugs for hepatorenal syndrome
1. All Cause Mortality 2. Serious Adverse Event 3. Hepatorenal Syndrome
outcomes:
Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease
1. All Cause Mortality 2. Cardiovascular Event 3. Injection related reaction 4. Hospital admission 5. Renal Hypertension 6. Quality of Life 7. Hyperkalaemia 8. Vascular access site thrombosis 9. Cardiovascular Mortality 10. Red Blood Cell Transfusion 11. Seizure 12. Cancer
outcomes:
Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients
1. Chill 2. Bacterial Infection 3. Urinary Tract Infection 4. Time-to-Event 5. Fever 6. Acute Rejection Of Renal Transplant 7. Clinical Improvement 8. Neurological Event 9. Graft loss 10. Disease Recurrence 11. Pyelonephritis 12. Treatment Failure 13. Malaise 14. Death
outcomes:
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients
1. All Cause Mortality 2. Graft loss 3. Cytomegalovirus Infection 4. Death 5. Diabetes Mellitus 6. Delayed graft function 7. Acute Rejection Of Renal Transplant 8. Cancer
outcomes:
Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients
1. Treatment Withdrawal 2. All Cause Mortality 3. Anemia 4. Quality of Life 5. Renal Hypertension 6. Cerebrovascular Events 7. Cardiovascular Mortality 8. Death 9. Red Blood Cell Transfusion 10. Arteriovenous Disorder 11. Thrombosis 12. Hemoglobin concentration
outcomes:
Interventions for chronic kidney disease‐associated restless legs syndrome
1. Restless Legs Syndrome 2. Clinical Improvement
outcomes:
Steroid avoidance or withdrawal for kidney transplant recipients
1. Graft loss 2. All Cause Mortality 3. Cytomegalovirus Infection 4. Death 5. Diabetes Mellitus 6. Acute Rejection Of Renal Transplant
outcomes:
Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units
1. All Cause Mortality 2. Haemodialysis 3. Adverse Event 4. Hepatitis C Virus
outcomes:
Normal saline versus lower‐chloride solutions for kidney transplantation
1. Hyperkalaemia 2. Delayed graft function
outcomes:
Interventions for lowering plasma homocysteine levels in dialysis patients
1. Cardiovascular Mortality
outcomes:
Laparoendoscopic single‐site donor nephrectomy (LESS‐DN) versus standard laparoscopic donor nephrectomy
1. Postoperative Pain 2. Intraoperative Hemorrhage 3. Duration Of Surgery 4. Complication
outcomes:
Antidepressants for treating depression in adults with end‐stage kidney disease treated with dialysis
1. Dizziness 2. All Cause Mortality 3. Sexual dysfunction 4. Nausea 5. Low Blood Pressure 6. Adverse Event 7. Health-Related Quality of Life
outcomes:
Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end‐stage kidney disease
1. Device malfunction 2. Thrombosis
outcomes:
Pre‐emptive correction for haemodialysis arteriovenous access stenosis
1. Venous Patency 2. Angiography 3. Poor venous access 4. Vascular access site thrombosis 5. Death 6. Secondary Patency 7. Primary Patency
outcomes:
Early versus delayed erythropoietin for the anaemia of end‐stage kidney disease
1. All Cause Mortality 2. Quality of Life 3. Cardiovascular Mortality
outcomes:
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients
1. Graft loss 2. All Cause Mortality 3. Cytomegalovirus Infection 4. Cancer 5. Acute Rejection Of Renal Transplant 6. Chronic rejection of renal transplant
outcomes:
Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function
1. Increased Serum Creatinine
outcomes:
Citrate salts for preventing and treating calcium containing kidney stones in adults
1. Clinical Improvement
outcomes:
Dietary interventions for mineral and bone disorder in people with chronic kidney disease
1. Alkaline Phosphatase level 2. Serum Phosphate 3. Cardiovascular Event 4. Human Fibroblast Growth Factor 5. Death 6. Phosphorus 7. Fracture 8. Serum Calcium 9. Serum Parathyroid Hormone Measurement
outcomes:
Nonsteroidal anti‐inflammatory drugs (NSAIDs) and non‐opioids for acute renal colic
1. Analgesic Effect 2. Pain 3. Rescue Medication 4. Symptom recurrence 5. Pain Relief
outcomes:
Haemodiafiltration, haemofiltration and haemodialysis for end‐stage kidney disease
1. All Cause Mortality 2. Cardiovascular Event 3. Cardiovascular Mortality 4. Health-Related Quality of Life
outcomes:
Interventions for lowering plasma homocysteine levels in kidney transplant recipients
1. Cardiovascular Mortality
outcomes:
Bicarbonate‐ versus lactate‐buffered solutions for acute continuous haemodiafiltration or haemofiltration
1. Hypotensive Episode 2. Relapse 3. Serum pH 4. Length Of Stay 5. Base Excess 6. Bicarbonate 7. Serum Creatinine 8. Death 9. Duration Of Hospital Stay 10. Cardiovascular System Complication Of Procedure 11. Intensive Care 12. Serum Lactate Dehydrogenase 13. Measurement of Partial Pressure Of Carbon Dioxide In Blood
outcomes:
Loop diuretics for patients receiving blood transfusions
1. Pulmonary Edema 2. Tachycardia 3. Positive Fluid Balance 4. Acute Respiratory Distress 5. Elevated Blood Pressure 6. Acute Lung Injury
outcomes:
Belatacept for kidney transplant recipients
1. Post-transplant Lymphoproliferative Disorder 2. Infection 3. Renal Scarring 4. Antihypertensive Therapy 5. Diabetes Mellitus 6. Survival 7. Acute Rejection Of Renal Transplant 8. Delayed Renal Graft Function 9. Cancer
outcomes:
Oral adsorbents for preventing or delaying the progression of chronic kidney disease
1. All Cause Mortality 2. End Stage Kidney Disease
outcomes:
Androgens for the anaemia of chronic kidney disease in adults
1. Anemia 2. Death
outcomes:
Dietary interventions for preventing complications in idiopathic hypercalciuria
1. Bone Density 2. Renal Colic 3. Quality of Life 4. Urinary Symptoms 5. Kidney Stone
outcomes:
HMG CoA reductase inhibitors (statins) for kidney transplant recipients
1. All Cause Mortality 2. Cardiovascular Event 3. Cardiovascular Mortality
outcomes:
Lipid‐lowering agents for nephrotic syndrome
1. All Cause Mortality 2. Measurement Of Serum Triglyceride Level 3. Serum Creatinine 4. Serum Cholesterol 5. Serum Ldl Cholesterol Measurement 6. Blood urea nitrogen 7. Serum Hdl Cholesterol Measurement
outcomes:
Percussion, diuresis, and inversion therapy for the passage of lower pole kidney stones following shock wave lithotripsy
1. Clinical effectiveness 2. Treatment Success
outcomes:
Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit
1. All Cause Mortality 2. Stroke 3. Serious Adverse Event 4. Quality of Life 5. Sepsis 6. Lung injury 7. Acute Myocardial Infarction
outcomes:
Nicotine receptor partial agonists for smoking cessation
1. Serious Adverse Event 2. Tobacco abstinence 3. Nausea
outcomes:
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
1. Forced Expiratory Volume 1 2. Quality of Life 3. COPD Exacerbation 4. Adverse Event
outcomes:
Inhaled corticosteroids versus placebo  for stable chronic obstructive pulmonary disease
1. Lung function test
outcomes:
Exercise‐based rehabilitation programmes for pulmonary hypertension
1. Exercise Test Finding 2. Quality of Life 3. Adverse Event
outcomes:
Pharmacological treatment for central sleep apnoea in adults
1. Central Sleep Apnea Syndrome 2. Serious Adverse Event 3. Cardiovascular Care 4. Quality Of Sleep 5. Quality of Life 6. Death 7. Adverse Event 8. Daytime Sleepiness 9. Apnoea Hypopnoea Index
outcomes:
Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary disease (COPD)
1. Borg Scale 2. Dyspnea 3. Exercise Capacity 4. Health-Related Quality of Life
outcomes:
Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease
1. All Cause Mortality 2. Acute Exacerbation Of Chronic Bronchitis 3. Hospitalization 4. COPD Exacerbation
outcomes:
Non‐invasive positive pressure ventilation for central sleep apnoea in adults
1. Central Sleep Apnea Syndrome 2. Serious Adverse Event 3. Death
outcomes:
Pulmonary rehabilitation versus usual care for adults with asthma
1. Exercise Test Finding 2. Asthma Control 3. Health-Related Quality of Life 4. Asthma Control Test 5. Asthma Control Questionnaire
outcomes:
Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease
1. Serious Adverse Event 2. Hospitalization 3. Intensive Care 4. Non-invasive mechanical ventilation
outcomes:
Interventions for preventing weight gain after smoking cessation
1. Smoking cessation 2. Body weight
outcomes:
Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea
1. Serious Adverse Event 2. International Index Of Erectile Function
outcomes:
Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive pulmonary disease
1. 6-minute Walk Test 2. Chronic Respiratory Disease Questionnaire 3. Death 4. Hospitalization 5. COPD Exacerbation 6. Adverse Event 7. Health-Related Quality of Life
outcomes:
Chronic non‐invasive ventilation for chronic obstructive pulmonary disease
1. All Cause Mortality 2. 6-minute Walk Test 3. St George Hospital Respiratory Questionnaire 4. Arterial Blood Gases 5. Survival 6. Health-Related Quality of Life
outcomes:
Glucocorticoid with cyclophosphamide for oral paraquat poisoning
1. Infection 2. All Cause Mortality 3. Death 4. Paraquat Toxicity
outcomes:
Combination fixed‐dose beta agonist and steroid inhaler as required for adults or children with mild asthma
1. Seen In Urgent Care Centre 2. Emergency Department Patient Visit 3. Hospitalization 4. Asthma Control 5. Adverse Event 6. Asthma exacerbation 7. Reduction Of Corticosteroid Dosage 8. Asthma Control Questionnaire
outcomes:
Interventions for tobacco cessation delivered by dental professionals
1. Smoking cessation 2. Tobacco abstinence 3. Behavior
outcomes:
Telerehabilitation for chronic respiratory disease
1. Dyspnea 2. St George Hospital Respiratory Questionnaire 3. 6-minute Walk Test 4. Chronic Respiratory Disease Questionnaire 5. Exercise Test Finding 6. Quality of Life 7. COPD Assessment Test 8. Adverse Event
outcomes:
Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta‐analysis
1. Serious Adverse Event 2. St George Hospital Respiratory Questionnaire 3. Quality of Life 4. Death 5. COPD Exacerbation 6. Drug Resistance
outcomes:
Anti‐IL‐5 therapies for chronic obstructive pulmonary disease
1. Forced Expiratory Volume 1 2. Serious Adverse Event 3. St George Hospital Respiratory Questionnaire 4. Chronic Respiratory Disease Questionnaire 5. Quality of Life 6. Hospitalization 7. COPD Exacerbation 8. Time-to-Event
outcomes:
Proton pump inhibitors for chronic obstructive pulmonary disease
1. Pneumonia 2. Serious Adverse Event 3. Acute Respiratory Failure 4. Quality of Life 5. COPD Exacerbation 6. Time-to-Event
outcomes:
Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. St George Hospital Respiratory Questionnaire 4. Psychiatric Symptom 5. Diarrhea 6. Quality of Life 7. Death 8. COPD Exacerbation 9. Peak Expiratory Flow Rate 10. Adverse Event
outcomes:
Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD)
1. Changes In Physical Activity 2. Physical Activity Level
outcomes:
Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea
1. Withdrawn From Research Study 2. Continuous Positive Airway Pressure Ventilation 3. Ess - Epworth Sleepiness Scale
outcomes:
Breathing exercises for adults with asthma
1. Forced Expiratory Volume 1 2. Quality of Life 3. Hospitalization 4. Asthma Control 5. Absenteeism 6. Asthma Quality of Life Questionnaire 7. Asthma exacerbation 8. Asthma symptoms 9. Asthma Control Questionnaire
outcomes:
Oxygen therapy in the pre‐hospital setting for acute exacerbations of chronic obstructive pulmonary disease
1. Ventilation Finding 2. Death 3. Duration Of Hospital Stay 4. Arterial Blood Gases
outcomes:
Pressure modification or humidification for improving usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea
1. Withdrawn From Research Study 2. Blood Pressure 3. Continuous Positive Airway Pressure Ventilation 4. Quality of Life 5. Functional Outcomes of Sleep Questionnaire 6. Ess - Epworth Sleepiness Scale 7. Adverse Event 8. Apnoea Hypopnoea Index
outcomes:
Pharmacological agents for adults with acute respiratory distress syndrome
1. All Cause Mortality 2. Weaning From Mechanically Assisted Ventilation 3. Serious Adverse Event 4. Adverse Event 5. Return to Work 6. Mechanical ventilation
outcomes:
Positional therapy for obstructive sleep apnoea
1. Short Form Health Survey - 36 2. Quality Of Sleep 3. Quality of Life 4. Ess - Epworth Sleepiness Scale 5. Patient compliance 6. Adverse Event 7. Sleepiness 8. Cognitive impairment 9. Apnoea Hypopnoea Index 10. Patient-Reported Outcome
outcomes:
Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
1. Forced Expiratory Volume 1 2. Serious Adverse Event 3. St George Hospital Respiratory Questionnaire 4. Chronic Respiratory Disease Questionnaire 5. Death 6. COPD Exacerbation 7. Adverse Event 8. Health-Related Quality of Life
outcomes:
Print‐based self‐help interventions for smoking cessation
1. Tobacco abstinence
outcomes:
Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)
1. Forced Expiratory Volume 1 2. Serious Adverse Event 3. Quality of Life 4. Hospitalization 5. COPD Exacerbation 6. Adverse Event 7. Clinical Improvement
outcomes:
Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with chronic obstructive pulmonary disease
1. Dyspnea 2. Serious Adverse Event 3. Quality of Life
outcomes:
Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease
1. Pneumonia 2. Serious Adverse Event 3. St George Hospital Respiratory Questionnaire 4. 6-minute Walk Test 5. Physical Activity Level 6. Quality of Life 7. Death 8. Hospitalization 9. Intubation 10. COPD Exacerbation
outcomes:
Enhancing partner support to improve smoking cessation
1. Smoking cessation
outcomes:
Nicotine replacement therapy versus control for smoking cessation
1. Smoking cessation 2. Limited supportive care 3. Intensive support
outcomes:
Self‐management for bronchiectasis
1. Acute Exacerbation Of Bronchiectasis 2. Quality of Life 3. Adverse Event
outcomes:
Family and carer smoking control programmes for reducing children's exposure to environmental tobacco smoke
1. Costs and Cost Analysis 2. Exposure To Environmental Pollution 3. Tobacco Smoking Behavior 4. Postpartum 5. Hospitalization 6. General Body State Finding 7. Exposed To Tobacco Smoke In Public Places 8. Exposed To Tobacco Smoke At Home 9. Behavior 10. Counseling 11. Respiratory finding 12. Behavioral change 13. Telephone Counseling
outcomes:
Singing for adults with chronic obstructive pulmonary disease
1. SF-36 Physical Function Score 2. Dyspnea 3. St George Hospital Respiratory Questionnaire 4. Short Form Health Survey - 36 5. Health-Related Quality of Life
outcomes:
Nursing interventions for smoking cessation
1. Smoking cessation
outcomes:
Invasive versus non‐invasive ventilation for acute respiratory failure in neuromuscular disease and chest wall disorders
1. Death 2. Survival
outcomes:
Inhaled magnesium sulfate in the treatment of acute asthma
1. Forced Expiratory Volume 1 2. Clinical Finding 3. Hospitalization 4. Peak Expiratory Flow Rate 5. Adverse Event
outcomes:
Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants
1. Bronchopulmonary Dysplasia Of Newborn 2. Death 3. Neonatal Death 4. Oxygen Supplementation
outcomes:
Neurally adjusted ventilatory assist compared to other forms of triggered ventilation for neonatal respiratory support
1. Pneumothorax 2. Intraventricular Hemorrhage 3. Bronchopulmonary Dysplasia Of Newborn 4. Death
outcomes:
Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates
1. Hyperglycemia 2. Bronchopulmonary Dysplasia Of Newborn 3. Death 4. Mechanical ventilation 5. Patent Ductus Arteriosus 6. Oxygen Supplementation 7. Asthma
outcomes:
Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants
1. Disability 2. Hyperglycemia 3. Systolic Blood Pressure 4. Diastolic Blood Pressure 5. Bronchopulmonary Dysplasia Of Newborn 6. Death 7. Intellectual Disability 8. Hypertensive disorder 9. Asthma
outcomes:
Shared decision‐making for people with asthma
1. Quality of Life 2. Medication adherence 3. Adverse Event 4. Asthma exacerbation 5. Patient Satisfaction
outcomes:
Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis
1. Acute Exacerbation Of Bronchiectasis 2. Quality of Life 3. Hospitalization 4. Cough
outcomes:
Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
1. Hospitalization 2. Asthma exacerbation
outcomes:
Culture‐specific programs for children and adults from minority groups who have asthma
1. Hospitalization 2. Asthma exacerbation
outcomes:
Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS)
1. All Cause Mortality
outcomes:
Self‐management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease
1. Quality of Life 2. Hospitalization
outcomes:
ProSeal versus Classic laryngeal mask airway (LMA) for positive pressure ventilation in adults undergoing elective surgery
1. Mechanical ventilation
outcomes:
Non‐invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease
1. Death 2. Endotracheal intubation
outcomes:
Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD)
1. Quality of Life 2. COPD Exacerbation 3. Adverse Event
outcomes:
Mass media interventions for preventing smoking in young people
1. Tobacco Smoking Consumption 2. Tobacco Smoking Behavior
outcomes:
Computer and mobile technology interventions for self‐management in chronic obstructive pulmonary disease
1. Clinical Chronic Obstructive Pulmonary Disease Questionnaire 2. Smoking cessation 3. Self Efficacy 4. St George Hospital Respiratory Questionnaire 5. 6-minute Walk Test 6. Depression 7. Anxiety 8. Hospitalization 9. COPD Exacerbation 10. Health-Related Quality of Life
outcomes:
Tobacco packaging design for reducing tobacco use
1. Tobacco Smoking Consumption 2. Tobacco Use 3. Tobacco Use And Exposure 4. Stopped Smoking 5. Patient-Reported Outcome
outcomes:
Lay‐led and peer support interventions for adolescents with asthma
1. Quality of Life 2. Medication adherence 3. Asthma exacerbation 4. Adverse Event
outcomes:
Interventions to improve adherence to inhaled steroids for asthma
1. Medication adherence 2. Absenteeism 3. Asthma exacerbation
outcomes:
Asthma education for school staff
1. Emergency Care 2. Death
outcomes:
Group behaviour therapy programmes for smoking cessation
1. Smoking cessation 2. Tobacco abstinence
outcomes:
Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease
1. Beck Anxiety Inventory 2. Quality of Life 3. Anxiety 4. Anxiety Symptoms 5. Adverse Event 6. Exercise Capacity Decreased
outcomes:
Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma
1. Forced Expiratory Volume 1 2. Asthma Daytime Symptoms 3. Death 4. Peak Expiratory Flow Rate 5. Adverse Event 6. Asthma exacerbation
outcomes:
Interventions to improve inhaler technique for people with asthma
1. Assessment Of Inhalation Technique 2. Quality of Life 3. Asthma Control 4. Asthma exacerbation
outcomes:
System change interventions for smoking cessation
1. Counseling About Tobacco Use 2. Smoking Cessation Therapy 3. Pharmacotherapy 4. Quiline enrolment 5. Tobacco Use 6. Stopped Smoking 7. Nicotine 8. Quitline referral
outcomes:
Fluid restriction for treatment of preterm infants with chronic lung disease
1. Apnea 2. Death 3. Hospitalization 4. Weight Gain 5. Oxygen Supplementation
outcomes:
Stepping down the dose of inhaled corticosteroids for adults with asthma
1. Forced Expiratory Volume 1 2. Adverse Drug Reaction 3. Serious Adverse Event 4. Asthma Control 5. Asthma Quality of Life Questionnaire 6. Asthma exacerbation 7. Health-Related Quality of Life
outcomes:
Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
1. Forced Expiratory Volume 1 2. Pneumonia 3. Death 4. COPD Exacerbation 5. Health Care Utilization
outcomes:
Combined inhaled beta‐agonist and anticholinergic agents for emergency management in adults with asthma
1. Forced Expiratory Volume 1 2. Relapse 3. Hospitalization 4. Peak Expiratory Flow Rate 5. Adverse Event
outcomes:
Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease
1. Emergency Care 2. Death 3. Hospitalization
outcomes:
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease
1. Quality of Life 2. Death 3. Hospitalization 4. Walking Distance Test
outcomes:
Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy
1. Dyspnea
outcomes:
Upper limb exercise training for COPD
1. Dyspnea 2. Quality of Life 3. Upper Limb Strength 4. Upper Limb Exercise Capacity
outcomes:
Exhaled nitric oxide levels to guide treatment for children with asthma
1. Corticosteroids - Inhaled 2. Hospitalization 3. Asthma exacerbation 4. Oral Steroid Therapy
outcomes:
Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
1. Forced Expiratory Volume 1 2. Adverse Event
outcomes:
Smoking cessation for people with chronic obstructive pulmonary disease
1. Smoking cessation
outcomes:
Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants
1. Extracorporeal Membrane Oxygenation 2. Neurological Impairment 3. Hearing impairment 4. Death 5. Cerebral Palsy 6. Mechanical ventilation 7. Neurodevelopmental Delay
outcomes:
Home telemonitoring and remote feedback between clinic visits for asthma
1. Quality of Life 2. Death 3. Hospitalization 4. Asthma exacerbation 5. Adverse Event
outcomes:
Guanylate cyclase stimulators for pulmonary hypertension
1. Exercise Test Finding 2. Death 3. Adverse Event
outcomes:
Codeine versus placebo for chronic cough in children
1. Serious Adverse Event 2. Treatment Failure 3. Clinical Improvement
outcomes:
Ambulatory and short‐burst oxygen for interstitial lung disease
1. Borg Scale 2. Dyspnea 3. Serious Adverse Event 4. 6-minute Walk Test 5. Endurance Shuttle Walk Test 6. Bicycle Ergometry 7. Exercise Capacity 8. Health-Related Quality of Life
outcomes:
Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
1. Pneumonia 2. Exercise Tolerance Finding 3. Quality of Life 4. Death 5. Hospitalization 6. COPD Exacerbation 7. Adverse Event
outcomes:
Different oral corticosteroid regimens for acute asthma
1. Hospitalization 2. Lung function test 3. Asthma exacerbation 4. Adverse Event
outcomes:
Intravenous magnesium sulfate for treating children with acute asthma in the emergency department
1. Emergency Care 2. Hospitalization
outcomes:
Remote versus face‐to‐face check‐ups for asthma
1. Quality of Life 2. Death 3. Lung function test 4. Asthma exacerbation 5. Adverse Event
outcomes:
Breathing exercises for children with asthma
1. Asthma Daytime Symptoms 2. Quality of Life 3. Adverse Event
outcomes:
High‐frequency oscillatory ventilation versus conventional ventilation for acute respiratory distress syndrome
1. Treatment Failure 2. Death 3. Low Blood Pressure 4. Accident Due To Extremes Of Atmospheric Pressure And To Sudden Changes In Atmospheric Pressure 5. Mechanical ventilation
outcomes:
Combined pharmacotherapy and behavioural interventions for smoking cessation
1. Smoking cessation 2. Tobacco abstinence
outcomes:
Protocolized versus non‐protocolized weaning for reducing the duration of invasive mechanical ventilation in newborn infants
1. Mechanical ventilation
outcomes:
Smoking cessation advice for people with serious mental illness
1. Smoking cessation 2. Tobacco Smoking Behavior 3. Quality of Life
outcomes:
Inhaled non‐steroid anti‐inflammatories for children and adults with bronchiectasis
1. Forced Expiratory Volume 1 2. Quality Of Life Scale 3. Quality of Life
outcomes:
Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta2‐agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma
1. Serious Adverse Event 2. Quality of Life 3. Asthma exacerbation
outcomes:
Comparison of animal‐derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants
1. Pulmonary Hemorrhage 2. Chronic Lung Disease 3. Pneumothorax 4. Intraventricular Hemorrhage 5. Hearing impairment 6. Blindness 7. Death 8. Cerebral Palsy 9. Oxygen Supplementation 10. Neurodevelopmental Delay
outcomes:
Addition of long‐acting beta2‐agonists to inhaled corticosteroids for chronic asthma in children
1. Forced Expiratory Volume 1 2. Withdrawn From Research Study 3. Serious Adverse Event 4. Peak Expiratory Flow Rate 5. Asthma exacerbation 6. Adverse Event
outcomes:
Airway clearance techniques for bronchiectasis
1. Acute Exacerbation Of Bronchiectasis 2. Quality of Life 3. Hospitalization
outcomes:
Interventions for enhancing adherence to treatment in adults with bronchiectasis
1. Acute Exacerbation Of Bronchiectasis 2. Assessment Of Compliance With Therapeutic Regimen
outcomes:
Exercise training to improve exercise capacity and quality of life in people with non‐malignant dust‐related respiratory diseases
1. 6-minute Walk Test 2. Cardiopulmonary Exercise Test 3. Exercise Capacity 4. Health-Related Quality of Life
outcomes:
Interventions for smokeless tobacco use cessation
1. Smoking cessation
outcomes:
Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease
1. Quality of Life 2. Death 3. Hospitalization
outcomes:
Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children
1. Emergency Care 2. Wheezing 3. Hospitalization 4. Adverse Event
outcomes:
Tonsillectomy or adenotonsillectomy versus non‐surgical management for obstructive sleep‐disordered breathing in children
1. Postoperative Hemorrhage 2. Attention Impaired 3. Postoperative Infection 4. Breathing-related Sleep Disorder 5. Secondary Post Tonsillectomy Hemorrhage 6. Dehydration 7. Quality Of Life Decreased 8. Postoperative Pain 9. Intraoperative Hemorrhage 10. Analgesia 11. Abnormal Sleep-related Events 12. Primary Post Tonsillectomy Hemorrhage 13. Behavior 14. Cognitive impairment
outcomes:
Calcium channel blockers for pulmonary arterial hypertension
1. Exercise Test Finding 2. New York Heart Classification Finding
outcomes:
Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease
1. Forced Expiratory Volume 1 2. Adverse Event
outcomes:
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma
1. Forced Expiratory Volume 1 2. Quality of Life 3. Hospitalization 4. Asthma exacerbation 5. Adverse Event
outcomes:
Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome
1. Chronic Lung Disease 2. Bronchopulmonary Dysplasia Of Newborn 3. Death 4. Oxygen Supplementation
outcomes:
Prolonged antibiotics for non‐cystic fibrosis bronchiectasis in children and adults
1. Acute Exacerbation Of Bronchiectasis 2. Quality of Life 3. Bacterial Resistance 4. Hospitalization
outcomes:
Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults
1. Asthma exacerbation 2. Adverse Event
outcomes:
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma
1. Forced Expiratory Volume 1 2. Quality Of Life Scale 3. Emergency Care 4. Serious Adverse Event 5. Quality of Life 6. Hospitalization 7. Asthma exacerbation
outcomes:
Effects of opioid, hypnotic and sedating medications on sleep‐disordered breathing in adults with obstructive sleep apnoea
1. Oxygen Desaturation Index 2. Oxygen Saturation 3. Apnoea Hypopnoea Index
outcomes:
Stopping long‐acting beta2‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
1. Asthma exacerbation 2. Adverse Event
outcomes:
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma
1. Forced Expiratory Volume 1 2. Serious Adverse Event 3. Quality of Life 4. Hospitalization 5. Asthma Quality of Life Questionnaire 6. Adverse Event 7. Asthma exacerbation 8. Asthma Control Questionnaire
outcomes:
Stopping long‐acting beta2‐agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids
1. Asthma exacerbation 2. Adverse Event
outcomes:
Pulmonary rehabilitation for chronic obstructive pulmonary disease
1. Quality of Life 2. Bicycle Ergometry 3. Walking Distance Test
outcomes:
Pressure‐controlled versus volume‐controlled ventilation for acute respiratory failure due to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS)
1. Single organ failure 2. Quality of Life 3. Death 4. Accident Due To Extremes Of Atmospheric Pressure And To Sudden Changes In Atmospheric Pressure 5. Mechanical ventilation
outcomes:
Early versus late tracheostomy for critically ill patients
1. Pneumonia 2. Hospital discharge 3. Death 4. Intensive Care 5. Mechanical ventilation
outcomes:
Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease
1. Forced Expiratory Volume 1 2. Quality of Life
outcomes:
Alpha‐2 agonists for long‐term sedation during mechanical ventilation in critically ill patients
1. Coma 2. Bradycardia 3. Weaning From Mechanically Assisted Ventilation 4. Death 5. Intensive Care 6. Mechanical ventilation 7. At Risk For Delirium
outcomes:
Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants
1. Bronchopulmonary Dysplasia Of Newborn 2. Death 3. Oxygen Supplementation
outcomes:
Aclidinium bromide for stable chronic obstructive pulmonary disease
1. Quality of Life 2. Death 3. COPD Exacerbation
outcomes:
Automated weaning and SBT systems versus non‐automated weaning strategies for weaning time in invasively ventilated critically ill adults
1. Weaning From Mechanically Assisted Ventilation 2. Trial For Spontaneous Breathing 3. Death 4. Endotracheal Reintubation 5. Intensive Care 6. Mechanical ventilation 7. Time-to-Event 8. Extubation
outcomes:
Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease
1. Forced Expiratory Volume 1 2. Relapse 3. Hyperglycemia 4. Adverse Drug Reaction 5. Dyspnea 6. Treatment Failure 7. Death
outcomes:
Continuous positive airway pressure (CPAP) during the postoperative period for prevention of postoperative morbidity and mortality following major abdominal surgery
1. Pneumonia 2. All Cause Mortality 3. Atelectasis 4. Respiratory Complication 5. Death
outcomes:
Inhaled anticholinergics and short‐acting beta2‐agonists versus short‐acting beta2‐agonists alone for children with acute asthma in hospital
1. Hospitalization 2. Adverse Event
outcomes:
Tiotropium versus placebo for chronic obstructive pulmonary disease
1. Quality of Life 2. Death 3. Hospitalization 4. COPD Exacerbation
outcomes:
Water‐based exercise for adults with asthma
1. Emergency Care 2. Medication Dose Changed 3. Quality of Life 4. Lung function test 5. Asthma exacerbation 6. Adverse Event
outcomes:
Inhaled corticosteroids in children with persistent asthma: effects on growth
1. Growth Rate 2. Body Height
outcomes:
Inhaled corticosteroids in children with persistent asthma: dose‐response effects on growth
1. Body Mass Index 2. Body weight 3. Growth Rate 4. Body Height 5. Skeletal Maturity Survey
outcomes:
Ambulatory oxygen for people with chronic obstructive pulmonary disease who are not hypoxaemic at rest
1. Dyspnea 2. Exercise Test Finding 3. Quality of Life 4. Death 5. Adverse Event
outcomes:
Combination inhaled corticosteroids and long‐acting beta2‐agonists for children and adults with bronchiectasis
1. Acute Exacerbation Of Bronchiectasis 2. Quality Of Life Scale 3. Quality of Life
outcomes:
Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
1. Emergency Care 2. Hospitalization 3. Intensive Care 4. Lung function test 5. Adverse Event 6. Vital Signs
outcomes:
Written emotional disclosure for asthma
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. Quality of Life
outcomes:
Non‐invasive ventilation during exercise training for people with chronic obstructive pulmonary disease
1. Exercise Test Finding 2. Physical Activity Level 3. Quality of Life
outcomes:
Mucolytics for bronchiectasis
1. Acute Exacerbation Of Bronchiectasis 2. Forced Expiratory Volume 1 3. Death 4. Hospitalization 5. Adverse Event 6. Health-Related Quality of Life 7. Expectoration
outcomes:
Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis
1. Forced Expiratory Volume 1 2. Quality of Life
outcomes:
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
1. Pneumonia 2. Adverse Event
outcomes:
Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma
1. Hospitalization 2. Inflammation 3. Asthma exacerbation 4. Adverse Event
outcomes:
Water‐based exercise training for chronic obstructive pulmonary disease
1. Quality Of Life Scale 2. Exercise Test Finding 3. Quality of Life
outcomes:
Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children
1. Emergency Care 2. Hospitalization 3. Asthma exacerbation 4. Adverse Event
outcomes:
Noninvasive positive‐pressure ventilation as a weaning strategy for intubated adults with respiratory failure
1. All Cause Mortality 2. Nosocomial Pneumonia 3. Weaning Failure 4. Endotracheal Reintubation 5. Mechanical ventilation
outcomes:
Antibody induction therapy for lung transplant recipients
1. Infection 2. Serious Adverse Event 3. Acute Rejection Of Lung Transplant 4. Death 5. Adverse Event 6. Obliterative Bronchiolitis
outcomes:
Smartphone and tablet self management apps for asthma
1. Emergency Care 2. Current Symptoms Scale 3. Quality of Life 4. Asthma Finding 5. Hospitalization 6. Asthma exacerbation
outcomes:
Thyrotropin‐releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease
1. Chronic Lung Disease 2. Neonatal Respiratory Distress Syndrome 3. Neonatal Death
outcomes:
Prostaglandins before caesarean section for preventing neonatal respiratory distress
1. Apgar Score 2. Mechanical ventilation 3. Respiratory Distress
outcomes:
Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
1. Pneumonia 2. All Cause Mortality 3. Hospitalization 4. COPD Exacerbation
outcomes:
Long‐acting beta2‐agonists for chronic obstructive pulmonary disease
1. Forced Expiratory Volume 1 2. Death 3. COPD Exacerbation 4. Adverse Event
outcomes:
Beclometasone for chronic obstructive pulmonary disease
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. Pneumonia 4. Death
outcomes:
Addition of anti‐leukotriene agents to inhaled corticosteroids in children with persistent asthma
1. Forced Expiratory Volume 1 2. Hospitalization 3. Asthma exacerbation
outcomes:
Beta2‐agonists for exercise‐induced asthma
1. Forced Expiratory Volume 1